Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

This trial tests whether ensartinib — a targeted pill that blocks a cancer-driving protein called ALK — reduces the chance of lung cancer coming back after surgery in patients with early-stage non-small cell lung cancer (NSCLC) that has the ALK genetic abnormality. **You may be eligible if...** - You are 18 to 75 years old with completely removed (resected) stage IB to IIIA NSCLC - Your tumor is confirmed to have an ALK gene fusion (by genetic testing) - You have recovered from surgery and/or post-surgery chemotherapy - You have no signs of cancer recurrence **You may NOT be eligible if...** - You have received any targeted therapy or immunotherapy for lung cancer before - You have had lung radiation therapy previously - You have a known allergy to ensartinib - You have active interstitial lung disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.